ACRX News and Press, AcelRx Pharmaceuticals Inc. From 11/08/23

AcelRx Pharmaceuticals Inc. (ACRX) is expected to report $-0.29 for Q3 2023

2023-11-07 17:35:52 ET More on AcelRx Pharmaceuticals AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript AcelRx upgraded at HC Wainwright on likely authorization of anticoagulant Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals ...

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study PR Newswire Two KOLs will discuss recent quantitative market research on the use of anticoagulants in the dialysis circuit Discussion will also fo...

AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 PR Newswire HAYWARD, Calif. , Oct. 26, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the developme...

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study PR Newswire Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study...

2023-09-12 11:00:56 ET More on AcelRx Pharmaceuticals Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals Historical earnings data for AcelRx Pharmaceuticals Financial information for AcelRx Pharmaceuticals AcelRx upgraded at HC Wainwright on likely...

2023-08-18 18:33:45 ET More on AcelRx Pharmaceuticals AcelRx Pharmaceuticals launches ~$10M private placement of shares AcelRx adds 16% on plans to divest pain therapy AcelRx announces $7.5M direct offering of common stock and warrants AcelRx Pharma rises 8% ...

2023-08-10 20:16:06 ET AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Raffi Asadorian – Chief Financial Officer Vince Angotti – Chief Executive Officer Pam Palmer – Founder...

2023-08-10 16:09:11 ET AcelRx Pharmaceuticals press release ( NASDAQ: ACRX ): Q2 GAAP EPS of -$0.41 beats by $0.12 . Revenue of $0.25M beats by $0.18M . For further details see: AcelRx Pharmaceuticals GAAP EPS of -$0.41 beats by $0.12, revenue of $0.25M b...

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits...